Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Neuroepidemiology|August 1, 2012
Guillain-Barré syndrome incidence in a large United States cohort (2000-2009)Irene M Shui, Melisa D Rett, Eric Weintraub, et al.BMC Neurology|January 1, 2015
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosisDouglas L Arnold, Peter A Calabresi, Bernd C Kieseier, et al.Journal of Neurology|October 2, 2014
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE studyDouglas L Arnold, Ralf Gold, Ludwig Kappos, et al.Clinical Therapeutics|October 16, 2014
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studiesMariko Kita, Robert J Fox, Ralf Gold, et al.Journal of Neurology|July 4, 2014
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE studyDouglas L Arnold, Ralf Gold, Ludwig Kappos, et al.The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisRalf Gold, Ludwig Kappos, Douglas L Arnold, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE studyLudwig Kappos, Ralf Gold, Douglas L Arnold, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2014
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEBernd C Kieseier, Douglas L Arnold, Laura J Balcer, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 24, 2013
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM studyMariko Kita, Robert J Fox, J Theodore Phillips, et al.Epilepsia|March 5, 2026
Soticlestat as an adjunctive therapy in children and young adults with Dravet syndromeJoseph Sullivan, Kette Valente, Vicente Villanueva, et al.Pageof 3